Tp Therapeutics
Turning point therapeutics presents preclinical data for novel ret inhibitor candidate tpx 0046.
Tp therapeutics. Our team is passionate about changing the course of care for patients. Turning point develops kinase inhibitors a class of targeted cancer drugs that are designed to bind to cancer cells with greater precision and affinity than existing therapies. Turning point therapeutics announces full exercise of underwriters option to purchase additional shares in public offering of common stock. Mission vision turning point therapeutics is using novel science to address one of the greatest medical challenges of our time developing cancer therapies to overcome the resistance inherent in other approved cancer medicines.
Turning point therapeutics is a clinical stage biopharmaceutical company designing and developing novel small molecule targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Turning point therapeutics inc. Founded and led by pioneers of precision medicine.